-
1 Comment
Nippon Chemiphar Co., Ltd is currently in a long term downtrend where the price is trading 4.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.3.
Nippon Chemiphar Co., Ltd's total revenue rose by 7.5% to $9B since the same quarter in the previous year.
Its net income has increased by 73.6% to $592M since the same quarter in the previous year.
Based on the above factors, Nippon Chemiphar Co., Ltd gets an overall score of 3/5.
| Exchange | TSE |
|---|---|
| Sector | Healthcare |
| CurrencyCode | JPY |
| ISIN | JP3701600003 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.08 |
|---|---|
| Market Cap | 6B |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 6.6% |
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a URAT1 inhibitor for hyperuricemia, guot currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17729, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various types of creams. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4539.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
